However, it is difficult to cure patients of NSCLC, CRC, or SCCHN using EGFR TKIs or anti-EGFR antibodies, even when combined with chemotherapy, because tumors inevitably develop acquired resistance to EGFR-targeted therapies [6,7,8]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.